ESC 365 - Antitachycardia pacing and VT termination: fact or fancy? What is the impact on shock reduction from a patient's perspective?

EHRA Premium Access

Antitachycardia pacing and VT termination: fact or fancy? What is the impact on shock reduction from a patient's perspective?

Session: Sudden death prevention and ICD therapy: unsolved issues

Topic: Prevention

Speaker: Doctor U. Birgersdotter-Green (La Jolla, US)

Event: EHRA 2021

Congress Presentation

Add to my library

About the speaker

Doctor Ulrika Birgersdotter-Green

University of California San Diego, La Jolla (United States of America)

4 presentations

0 follower

4 more presentations in this session

Primary prevention in systolic dysfunction/heart failure patients: use, misuse, and underuse

Speaker: Associate Professor M. Zabel (Goettingen, DE)

No more therapy delivery after ventricular tachycardia ablation? Will my patient fear shock again?

Speaker: Doctor A. Berruezo Sanchez (Barcelona, ES)

Noninvasive risk factors for the prediction of inducibility on programmed ventricular stimulation in post-MI patients with ejection fraction over 40% at SCD risk, insights from the PRESERVE EF study

Speaker: Doctor K. Trachanas (Athens, GR)

Sudden death prevention and ICD therapy: unsolved issues - discussion

Access the full session

Sudden death prevention and ICD therapy: unsolved issues

Speakers: Doctor U. Birgersdotter-Green, Associate Professor M. Zabel, Doctor A. Berruezo Sanchez, Doctor K. Trachanas

About the event

EHRA 2021

23 April - 25 April 2021

Sessions Presentations

Congress

ESC 365 is supported by

Explore sponsored resources

Explore sponsored resources